Search
Feb 16, 2024
Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates
Carolyn Bertozzi introduces Firefly and explains the idea behind combining the science of antibody-drug conjugates with protein degraders
Feb 15, 2024
Wedbush analyst David Nierengarten joins BiotechTV for Analyst Thursdays from San Francisco
David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, and more.
Feb 15, 2024
A deep dive into the science of immuno-neurology with the CEO of Alector
Arnon Rosenthal walks us through the idea of the immune system playing a central role in neuro-degeneration
Feb 14, 2024
ALX Oncology's CEO on CD47 after Gilead's magrolimab news last week, and why he believes his asset is fundamentally different
Jason Lettmann describes how he believes having an inactive Fc domain makes all the difference in the CD47 space.
Feb 13, 2024
Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics
Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.
Feb 12, 2024
How a PhD student at UPenn is working in a world-class cellular immunotherapy lab
Amanda Finck describes her interest in science and how it has led her to work in the Center for Cellular Immunotherapies at UPenn.
Feb 9, 2024
A deep dive into the science of prime editing with the CEO of Prime Medicine
Prime Medicine CEO Keith Gottesdiener describes the advantages he sees in prime editing.
Feb 9, 2024
The co-founder of Scion Life Sciences on coming out of stealth mode and the new $310 million venture fund announced this week
Aaron Kantoff describes Scion's mission and investment strategy and shares his thoughts on the current state of biotech.
Feb 8, 2024
Louis Kassa, an expert in the region, gives an overview of the Pennsylvania biopharma ecosystem
The CEO of the Pennsylvania Biotechnology Center, Hepatitis B Foundation, and Blumberg Institute talks about Pennsylvania biotech.
Feb 8, 2024
Children's Hospital of Philadelphia's Stephan Grupp on the sickle cell launches and the latest in CAR-T
Dr. Grupp describes the factors that might affect access, demand, and the longevity of the launches of the new sickle cell products.
Feb 7, 2024
Bruce Levine on UPenn's Center for Cellular Immunotherapies and his thoughts regarding FDA's recent CAR-T guidance
Dr. Levine highlights work being done at UPenn including a 3-day CAR with IL-18, a dual CAR targeting GBM
Feb 7, 2024
An overview of Philly biotech and the success of Spark with Jeff Marrazzo
Jeff Marrazzo describes the strengths that Philadelphia has to make it biotech's capital of cell and gene therapy.
Feb 2, 2024
Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease
Noland Townsend describes the science behind Lexeo's lead programs.
Feb 2, 2024
Alto Neuroscience's CEO on today's $128.6 million NYSE IPO
Amit Etkin describes Alto's approach to tyring to bring precision medicine to psychiatry.
Feb 2, 2024
Five Questions with Xencor CEO Bassil Dahiyat
Bassil Dahiyat walks us through the latest advances in bi-specific antibody engineering and gives his take on L.A.'s biotech scene.
Feb 2, 2024
Talking IPOs and trends in science with NYSE's Eric Dimise
Eric Dimise, Site Lead, Healthcare & Life Sciences Capital Markets at NYSE, shares his thoughts on the optimism reverberating throughout the
Feb 1, 2024
The growth of RNAi as a platform with the CEO of Arrowhead Pharmaceuticals
Arrowhead CEO Chris Anzalone discusses the present and future of RNAi, and speaks on the company’s cardiometabolic and pulmonary programs.
Feb 1, 2024
Deutsche Bank's Neena Bitritto-Garg joins Analyst Thursdays to highlight the CNS space and more
Neena Bitritto-Garg joins Analyst Thursdays and talks Prothena, Sarepta, Acadia, Compass Pathways, Neumora, Sage, and Amylyx.
Feb 1, 2024
ImmPACT Bio's CEO on bispecifc CAR-T cells for cancer and autoimmune disease
Sumant Ramachandra describes why ImmPACT's programs target more than one antigen and the case for CD19/CD20 in oncology and autoimmune.
Jan 31, 2024
Terray Therapeutics' CEO on designing computational and experimental platforms to supercharge small molecule discovery
Jacob Berlin walks on the process that has allowed Terray to do well over 2 billion target / ligand binding measurements over 18 months.
.png){kind=logo}
